

1 **Title:** miR-1 coordinately regulates lysosomal v-ATPase and biogenesis to affect
2 muscle contractility upon proteotoxic challenge during ageing

3
4 ^{1, 8}Isabelle Schiffer, ^{1, 8}Birgit Gerisch, ^{1, 8}Kazuto Kawamura, ¹Raymond Laboy,
5 ^{1, 3}Jennifer Hewitt, ^{1, 2}Martin S. Denzel, ^{4, 5, 6}Marcelo A. Mori, ³Siva Vanapalli, ⁷Yidong
6 Shen, ¹Orsolya Symmons, ^{1, 2, 9}Adam Antebi

7
8 ¹Max Planck Institute for Biology of Ageing, Joseph Stelzmann Str. 9b, 50931, Cologne, Germany
9 ²Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD),
10 University of Cologne, 50931, Cologne, Germany

11 ³Department of Chemical Engineering, Texas Tech University, Lubbock, TX 79409, USA
12 ⁴Laboratory of Aging Biology, Department of Biochemistry and Tissue Biology, University of Campinas
13 (UNICAMP), Campinas, Brazil

14 ⁵Experimental Medicine Research Cluster (EMRC), University of Campinas (UNICAMP), Campinas,
15 Brazil

16 ⁶Obesity and Comorbidities Research Center (OCRC), University of Campinas (UNICAMP), Campinas,
17 Brazil

18 ⁷State Key Laboratory of Cell Biology, Innovation Center for Cell Signaling Network, CAS Center for
19 Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese
20 Academy of Sciences, University of Chinese Academy of Sciences

21 ⁸co-first author

22 ⁹corresponding author

23

24 Correspondence: aantebi@age.mpg.de

25

26 **Abstract**

27 Muscle function relies on the precise architecture of dynamic contractile elements,
28 which must be fine-tuned to maintain motility throughout life. Muscle is also highly
29 plastic, and remodelled in response to stress, growth, neural and metabolic inputs. The
30 evolutionarily conserved muscle-enriched microRNA, miR-1, regulates distinct aspects
31 of muscle biology during development, but whether it plays a role during ageing is
32 unknown. Here we investigated the role of *C. elegans* miR-1 in muscle function in
33 response to proteostatic stress during adulthood. *mir-1* deletion results in improved
34 mid-life muscle motility, pharyngeal pumping, and organismal longevity under
35 conditions of polyglutamine repeat proteotoxic challenge. We identified multiple
36 vacuolar ATPase subunits as subject to miR-1 control, and the regulatory subunit *vha-*
37 *13/ATP6VIA* as a direct target downregulated via its 3'UTR to mediate miR-1
38 physiology. miR-1 further regulates nuclear localization of lysosomal biogenesis factor
39 *HLH-30/TFEB* and lysosomal acidification. In summary, our studies reveal that miR-1
40 coordinately regulates lysosomal v-ATPase and biogenesis to impact muscle function
41 and health during ageing.

42

43

44

45 **Introduction**

46 Ageing is the major cause of progressive decline in all organ systems
47 throughout the body. This is particularly evident in the musculature and often manifests
48 as sarcopenia, the loss of muscle mass and strength. In fact, muscle frailty is a
49 hallmark of tissue ageing seen in species as diverse as worms, flies, mice and humans
50 (Herndon et al., 2002; Miller et al., 2008) (V. G. Martinez et al., 2007) (Demontis,
51 Piccirillo, Goldberg, & Perrimon, 2013) (Cruz-Jentoft et al., 2010) (Nair, 2005). At the
52 molecular level, frailty is often accompanied by a decline in muscle structure and
53 function, as well as alterations in muscle proteostasis and metabolism. Nevertheless,
54 muscle can respond positively to exercise and stress and rejuvenate even into older
55 age, showing remarkable plasticity (Pollock et al., 2018) (Cartee, Hepple, Bamman, &
56 Zierath, 2016) (Distefano & Goodpaster, 2018). A molecular study of muscle ageing
57 and plasticity in a genetically tractable model could shed light on fundamental aspects
58 of these processes.

59 microRNAs are small 22-26 nucleotide RNAs that bind with complementarity
60 through their seed sequence to target mRNAs to downregulate gene expression (Gu
61 & Kay, 2010). They can work as molecular switches or fine tune gene regulation, and
62 typically have multiple targets, thereby coordinating cellular programs. Many
63 microRNAs are expressed in a tissue-specific manner and regulate programs cell
64 autonomously, and could therefore potentially serve as tissue-specific therapeutic
65 targets (Guo et al., 2014) (Panwar, Omenn, & Guan, 2017). In addition, some
66 microRNAs are found circulating in serum (Weber et al., 2010) (Chen et al., 2008),
67 raising the possibility that they can act cell non-autonomously as well.

68 miR-1 homologs are muscle-enriched microRNAs that are highly conserved in
69 evolution, and important for mammalian heart and muscle development (Zhao et al.,
70 2007). Like in other animals, *Caenorhabditis elegans* *mir-1* is expressed in body wall
71 (“skeletal”) and pharyngeal (“cardiac”) muscle (Simon et al., 2008). Deletion mutants
72 are viable and exhibit modest changes in the behavior of the neuromuscular junction
73 (Simon et al., 2008) and autophagy (Nehammer et al., 2019), but little else is known of
74 its normative function. In this work, we examined the potential role of miR-1 in
75 regulating muscle function and proteostasis. Surprisingly, we found that under polyQ35
76 proteotoxic challenge, *mir-1* mutation prevents aggregate formation, and increases
77 organismal motility and pharyngeal contractility during ageing. Mechanistically, miR-1

78 regulates expression of several lysosomal v-ATPase subunits, and targets a crucial
79 regulatory component, *vha-13/ATP6VIA*, via its 3' UTR to impact proteotoxicity and
80 longevity. Further, miR-1 regulates lysosomal acidification and nuclear localization of
81 HLH-30/TFEB, a key regulator of lysosome biogenesis. These studies reveal an
82 unexpected role of miR-1 in coordinating lysosomal function and health during ageing.

83

84


85 **Results**

86 ***mir-1* mutation improves muscle motility upon polyQ challenge**

87 *mir-1* is a highly conserved microRNA expressed predominantly in muscle
88 tissues including pharyngeal muscle, body wall muscle, and sex muscles (Andachi &
89 Kohara, 2016; N. J. Martinez et al., 2008). To unravel molecular miR-1 function, we
90 first characterized the nature of several *mir-1* mutations. The reference alleles (*n4101*,
91 *n4102*) consist of large deletions of the region that could have confounding effects on
92 nearby loci. We therefore focused on *gk276*, a smaller 192 base pair deletion that
93 removes the *mir-1* coding region as well as the downstream non-coding region. We
94 also generated an independent *mir-1* allele, *dh1111*, by CRISPR genome engineering
95 (Figure 1A), which deletes a 52 base pair region within the *mir-1* locus. Both alleles
96 failed to express the mature miRNA as measured by Taqman qPCR (Supplemental
97 Figure 1A), and thus are *mir-1* null mutants.

98 To investigate *mir-1* function, we measured several physiological parameters.
99 We found that *mir-1* mutants *gk276* and *dh1111* developed normally, had normal brood
100 size, and near normal life span (Supplemental Figure 1B-D, Supplemental Table 1).
101 Additionally, motility on solid media, thrashing in liquid culture, and pharyngeal
102 pumping ability determined at day 8 and 14 of adulthood were similar to wild-type N2
103 controls (Supplemental Figure 1E-G, Supplemental Table 2). Since *mir-1* deletion
104 showed little obvious phenotype on its own, we reasoned that some physiological
105 differences might emerge under stress. However, we saw little distinction from wild-
106 type (WT) with moderate heat stress by growth at 25°C nor heat shock resistance at
107 35°C (Supplemental Figure 1D and H, Supplemental Table 1).

108



109

110 **Figure 1. *mir-1* mutants exhibit improved motility upon polyQ challenge.**

111 **(A)** Schematic showing the *mir-1* locus, deletion alleles *mir-1*(*gk276*) and *mir-1*(*dh1111*) (see Material
112 and Methods).

113 **(B)** Representative images of wild-type N2 and *mir-1* mutant animals expressing *unc-54p::Q35::YFP*
114 (Q35) showing loss of aggregates in the *mir-1* background on day 4 of adulthood. Arrowheads point to
115 aggregates. Scale bar 100 μ m. **(C)** Quantification of Q35::YFP aggregates in B using Zen software,

116 each dot represents one animal, mean \pm SEM from one representative experiment, N=3, one way
117 ANOVA, Tukey's multiple comparisons test, ***, p<0.001, ****, p<0.000, ns, not significant.
118 (D) Motility of indicated *mir-1* alleles and wild-type animals expressing *unc-54p::Q35::YFP*, measured
119 by the circle test, day 8 of adulthood. Percent worms that left the circle after 30 minutes was determined.
120 Each dot represents one experiment. Mean \pm SEM of N=6 to 8. One way ANOVA, ***, p<0.001, ****,
121 p<0.0001, ns, not significant.
122 (E) Motility of *mir-1* alleles and wild-type animals expressing *unc-54p::Q35::YFP*, measured by the
123 thrashing assay. 25 worms per condition, each dot represents one animal, mean \pm SEM from one
124 representative experiment, N=4, one way ANOVA, **, p<0.01 ***, p<0.001, ns, not significant.
125 CeleST analysis of activity index (F), brush stroke (G) and body wave (H) comparing N2 and *mir-*
126 *1(gk276)* mutant animals with or without *unc-54p::Q35::YFP* at day 4 and day 8 of adulthood. Each dot
127 represents one animal. t-test, *, p<0.05 **, p<0.01, ns, not significant.
128 (I) Pharyngeal pumping rate measured on day 8 of adulthood in *mir-1* alleles and wild-type animals
129 expressing *unc-54p::Q35::YFP*. Each dot represents one animal, mean \pm SEM from one representative
130 experiment, N=3, one way ANOVA, ****, p<0.0001, ns, not significant.
131 (J) Life span experiments of *mir-1* mutants and wild-type animals expressing *unc-54P::Q35::YFP*. One
132 experiment of N=3. t-test: N2;Q35 vs. *gk276*;Q35: p=0.03. N2;Q35 vs. *dh1111*;Q35: p<0.0001.
133 (K) Presence of an extrachromosomal *mir-1* transgene brings back aggregates in *mir-1(gk276)* mutants
134 at day 4 of adulthood, showing rescue by the transgene. Transgenic worms were compared to non-
135 transgenic segregants of the same strain. Scale bar 100 μ m. (L) Quantification of Q35::YFP aggregates
136 (from K), each dot represents total aggregate number of one animal, mean \pm SEM from one
137 representative experiment, N=3, t-test, ****, p<0.0001.
138 (M) Motility of *mir-1(gk276)* *unc-54p::Q35::YFP* animals in the presence or absence of the *mir-1*
139 transgene at day 8 of adulthood, measured by circle test. Each dot represents one experiment, mean \pm
140 SEM of N=7. Total number of worms tested 646 (transgenic worms) and 469 (non-transgenic segregants
141 of the same strain), t-test, **, p<0.01.
142 (N) Pharyngeal pumping rate of *mir-1(gk276)* *unc-54p::Q35::YFP* animals in the presence or absence
143 of the *mir-1* transgene. Transgenic worms were compared to non-transgenic segregants of the same
144 strain. Each dot represents one animal, mean \pm SEM from one representative experiment, N=7, t-test,
145 **, p<0.01.
146 (O) Life span experiments of *mir-1(gk276)* *unc-54p::Q35::YFP* animals in the presence or absence of
147 the *mir-1* transgene. Transgenic worms were compared to non-transgenic segregants of the same
148 strain. One representative experiment of N=5, t-test, p<0.0001.
149

150 We next tested the idea that *mir-1* mutants might differ in their response to
151 proteotoxic stress. To do so, we used a strain expressing polyglutamine-35 tracts fused
152 to yellow fluorescent protein (YFP) under the control of the muscle myosin specific
153 *unc-54* promoter (*unc-54p::Q35::YFP*), which has been used previously in models of
154 proteotoxicity and Huntington's disease (Morley, Brignull, Weyers, & Morimoto, 2002)

155 (Brignull, Morley, Garcia, & Morimoto, 2006). In these strains, initially soluble proteins
156 become sequestered into insoluble aggregates, visible as foci in the muscle of the
157 worm. Worms expressing the polyQ35 stretches showed progressive age-dependent
158 protein aggregation, which became clearly visible by day 4 of adulthood. Interestingly,
159 we observed that *mir-1* mutants displayed significantly less aggregates (avg. 38 and
160 36) compared to age-matched wild-type controls (avg. 53) at this time (Figure 1B and
161 C, Supplemental Table 2).

162 We further investigated the possible effect of proteotoxicity by measuring
163 organismal motility of Q35 strains using the circle test. This test measures how many
164 worms crawl out of a 1 cm circle within 30 minutes on day 8 of adulthood on agar
165 plates. Day 8 was chosen as a timepoint where paralysis becomes visible but animals
166 are still viable. We observed that about 30% of the *mir-1*;Q35 mutants left the circle
167 while only 2.5% of the control Q35 worms did so (Figure 1D, Supplemental Table 2).
168 We also measured motility by counting the thrashing rate in liquid culture on day 8 of
169 adulthood. Though the degree of paralysis was more variable, both *mir-1* mutants
170 *gk276* and *dh1111* were significantly more mobile (average 16, 15 body bends)
171 compared to age-matched wild-type controls (average 2 body bends, Figure 1E,
172 Supplemental Table 2).

173 To further characterize miR-1's impact on muscle function, we performed
174 CeleST analysis (Restif et al., 2014), a MATLAB based algorithm that extracts various
175 parameters of movement (wave initiation, travel speed, brush stroke, activity index)
176 and gait (wave number, asymmetry, curl, stretch) from video footage. Typically activity
177 measures decline with age, whereas gait abnormalities increase with age (Restif et al.,
178 2014). We scored animals focusing on day 4 and 8 of adulthood comparing *mir-1* and
179 WT, in the presence and absence of the Q35 array. In the absence of Q35, *mir-1*
180 mutants performed similar to WT (e.g., body wave) or were slightly different (wave
181 initiation, travel speed, stretch) for some parameters (Supplemental Table 3). In the
182 presence of Q35, however, *mir-1* mutants did significantly better than WT for several
183 measures of activity (activity index, brush stroke, travel speed, wave initiation) and gait
184 (body wave) on day 8 (Figure 1F-H, Supplemental Figure 1I-M, Supplemental Table
185 3), consistent with the idea that *mir-1* mutation protects against proteotoxic stress
186 during mid-life.

187 *mir-1* is also highly expressed in the pharynx, a contractile tissue similar to
188 cardiac muscle. We observed that in the *mir-1*;Q35 background, pumping rate was
189 significantly increased (*gk276*, avg. 60; *dh1111*, avg. 78) compared to Q35 controls
190 (avg. 16) on day 8 of adulthood (Figure 1I, Supplemental Table 2). Furthermore, we
191 found that the life span of *mir-1(dh1111)*;Q35 strains was significantly extended (n=3,
192 mean 13 (WT) vs.19 (*dh1111*) days) compared to Q35 alone (Figure 1J, Supplemental
193 Table 1). A similar trend was seen with *gk276* in 2 of 3 experiments (Figure 1J,
194 Supplemental Table 1). These findings suggest that *mir-1* reduction can counter the
195 intrinsic and systemic detrimental effects of Q35 proteotoxic challenge.

196 Introducing a wild-type *mir-1* transgene into the *mir-1(gk276)* background
197 restored normal levels of *mir-1* expression (Supplemental Figure 1N) and largely
198 reversed *mir-1* phenotypes, showing increased Q35 aggregates, decreased motility,
199 pumping rate, and life span compared to non-transgenic controls (Figure 1K-O,
200 Supplemental Table 1 and 2). The similarity of behaviour among the different *mir-1*
201 alleles and the rescue of these phenotypes by the wild-type transgene demonstrate
202 that the *mir-1* mutation is causal for removing muscle aggregates and improving mid-
203 life motility.

204

205 **v-ATPase subunits are downstream mediators of miR-1 induced motility 206 improvement**


207 To identify downstream mediators of protein quality control improvement in
208 *mir-1* mutants, we used computational and proteomic approaches to find potential miR-
209 1 targets. For the computational approach, we used publicly available prediction tools
210 to identify genes harbouring miR-1 seed binding sites in their 3'UTR, namely
211 microRNA.org, TargetScanWorm, and PicTar (Betel, Wilson, Gabow, Marks, &
212 Sander, 2008) (Jan, Friedman, Ruby, & Bartel, 2011) (Lall et al., 2006). These
213 prediction tools use distinct algorithms that often yield different and extensive sets of
214 candidates (Figure 2A). Therefore, we limited ourselves mostly to candidates that were
215 predicted as targets by all three algorithms. This yielded 68 overlapping candidates
216 (Figure 2A), 50 of which had available RNAi clones (Supplementary Table 4).
217 Interestingly, network analysis of these 68 genes using STRING (string-db.org) (Snel,
218 Lehmann, Bork, & Huynen, 2000) revealed a tight cluster of predicted targets encoding
219 11/21 subunits of the vacuolar ATPase (Figure 2B, Supplemental Figure S2A). 5

220 additional vacuolar ATPase genes were identified by 2 of the 3 prediction algorithms
221 (Supplemental Figure 2A). In addition, two genes that code transcription factors
222 implicated in lysosome biogenesis, *daf-16*/FOXO and *h/h-30*/TFEB (Sardiello et al.,
223 2009; Settembre et al., 2011), also contained predicted miR-1 binding sites in their
224 3'UTRs.

225 Next, we carried out a functional screen of the selected candidates. We
226 reasoned that *mir-1* deletion likely results in an upregulation of these proteins, and that
227 RNAi knockdown of the relevant genes should therefore abrogate the improved motility
228 of *mir-1*;Q35 worms. Specifically, we scored motility using a rapid version of the circle
229 test, measuring the ability of *mir-1*;Q35 worms grown on candidate RNAis to migrate
230 out of a 1 cm diameter circle within 1 minute (Figure 2C). 12/20 *mir-1*;Q35 worms left
231 the circle when grown on luciferase control RNAi (*luci*). We considered genes as
232 potential *mir-1*;Q35 suppressors if less than 4 worms left the circle upon RNAi knock
233 down of the genes, and prioritized candidates when only 0 or 1 worms left. Among the
234 selected candidates vacuolar ATPase subunits *vha-1*, *vha-8*, *vha-9*, *vha-13*, and *vha-*
235 14, as well as muscle gene *zyx-1*, stood out as molecules suppressing *mir-1* motility
236 (Figure 2C and Supplemental Figure 2D).

237 As a second parallel approach to identify miR-1 regulatory targets in an
238 unbiased manner, we performed TMT shotgun proteomic analysis, comparing *mir-1*
239 mutants to WT worms on day 1 of adulthood. We identified approximately 1,500-2,000
240 proteins in the replicates (Figure 2D). Samples showed a high degree of correlation
241 (Supplemental Figure 2B) with minimal separation of WT and *mir-1* genotypes,
242 reflecting the subtle changes induced by *mir-1* mutation at the organismal level. For
243 further analysis we therefore selected the 50 top upregulated proteins with available
244 RNAi clones and tested them for their ability to suppress the motility phenotype using
245 the circle test (Supplemental Figure 2C and 2E, Supplemental Table 5), among them
246 *vha-10*, *vha-19* and *zyx-1*, which had previously been predicted to harbour *mir-1*
247 binding sites.

248



249

250 **Figure 2. v-ATPase subunits are downstream mediators of *mir-1* induced
251 motility improvement.**

252 **(A)** Computational screen using *in silico* prediction of miR-1 binding sites in target mRNAs using
253 microRNA.org, TargetScan and PicTar identifies 68 shared candidates.
254 **(B)** STRING network analysis of predicted miR-1 targets reveals a cluster of vATPase subunits.
255 **(C)** Initial RNAi screen of computationally predicted candidates using the circle test on day 8 of
256 adulthood reveals a number of candidates that reduced motility of *mir-1*(gk276);Q35, 20 worms per
257 RNAi (N=1). Red line, number of luciferase controls that left the circle. v-ATPases are highlighted in red.
258 **(D)** Volcano plot of proteomic analysis showing differentially regulated proteins in *mir-1* vs. N2 animals.
259 Red dots show upregulated proteins tested in circle assay, VHA-10 and VHA-19 indicated by blue
260 triangles. N=6 (*mir-1*) and 4 (N2) biological replicates.

261 (E) Effect of v-ATPase subunit RNAi knockdown on *mir-1(gk276);Q35* motility as measured in the
262 thrashing assay. Animals are grown on the corresponding RNAi from L4 onwards. N=1. Mean \pm SEM,
263 one way ANOVA, only significant values are labelled: *, p<0.05, **, p<0.01.
264 (F) and (G) Motility assay (circle test) and thrashing assay on day 8 of *mir-1(gk276);Q35* worms upon
265 *vha-13*, *vha-5*, *daf-16* and *hlh-30* RNAi knockdown. Control, luciferase RNAi (*luci*). Mean \pm SEM of N=4,
266 one way ANOVA, *, p<0.05, ***, p<0.001, ****, p<0.0001, ns, not significant.
267 (H) Pumping assay of *mir-1(gk276);Q35* worms upon *vha-13*, *vha-5*, *daf-16* and *hlh-30* RNAi knockdown
268 on day 8 of adulthood. Control, luciferase RNAi (*luci*). N=3, mean \pm SEM, one way ANOVA, **, p<0.01,
269 ns, not significant.
270 (I) Life span of *mir-1;Q35* and Q35 worms upon *vha-13* RNAi knockdown. One experiment of N=3, t-
271 test: p<0.01.

272

273 Based on the prominent presence of vATPase genes among both the informatic
274 and the proteomic candidates, we systematically tested 10 of them in the thrashing
275 assay, confirming v-ATPase subunits *vha-1*, *vha-9*, *vha-13*, *vha-14* and *vha-19* as
276 likely mediators of *mir-1;Q35* motility (Figure 2E). We further tested the impact of *vha-*
277 *5*, *vha-13* and transcription factors *daf-16/FO XO* and *hlh-30/TFEB* RNAi on *mir-1;Q35*
278 phenotypes in more detail, using the circle test, thrashing assay and pharyngeal
279 pumping as readout (Figure 2F-H), which again confirmed in particular the role of *vha-*
280 *13* in reducing *mir-1* motility. We also confirmed that the effect on motility was specific
281 to the *mir-1* background for *vha-5*, *vha-10*, *vha-13* and *hlh-30*, since RNAi of these
282 genes had no significant effect on motility in N2;Q35 worms (Supplemental Figure 2F).

283 In summary, knockdown of 5 of 10 tested v-ATPase subunits from both the
284 computational and proteomics screen, as well as 2 transcriptional mediators of
285 lysosome biogenesis, reduced or abolished *mir-1* motility improvement either by circle
286 test or thrashing, revealing these molecules to have congruent physiological effects.
287 Therefore, we focused most of our further efforts on examining v-ATPase regulation
288 by miR-1.

289

290 miR-1 directly regulates VHA-13 protein levels in muscle tissue

291 MicroRNAs regulate their targets by binding to the 3' UTR of client mRNAs,
292 thereby decreasing RNA stability and translation. If miR-1 regulates v-ATPase
293 subunits, then miR-1 loss would be predicted to de-repress v-ATPase mRNA and

294 protein levels. Because the onset of Q35 aggregation becomes visible by day 4 of
295 adulthood, we examined the mRNA expression of representative v-ATPase subunits
296 at this time. We found that the mRNA levels of *vha-5*, *vha-10*, *vha-13*, and *vha-19*, as
297 well as transcription factors *hlh-30/TFEB* and *daf-16/FOXO* were increased
298 approximately 2-fold in *mir-1* mutants compared to age-matched wild-type worms
299 (Figure 3A), consistent with the idea that these genes are miR-1 targets.


300 To investigate whether miR-1 also regulates candidates at protein level, we
301 endogenously tagged the v-ATPase subunits *vha-5*, *vha-10*, *vha-13* and *vha-19* by
302 CRISPR/Cas9 using an N-terminal 3xFlag-mNeonGreen-tag. Tagging *vha-19* and
303 *vha-10* caused lethality and were not pursued further. Tagged *vha-5* showed significant
304 upregulation in the pharynx in *mir-1* mutants compared to wild-type, but not in vulva
305 muscle (Supplementary Figure 3A and B, Supplemental Table 7). Furthermore, RNAi
306 knockdown only weakly suppressed *mir-1* motility (Figure 2E-G, Supplemental Table
307 S2). N-terminally tagged *vha-13(syb586)*, however, was viable, showed expression
308 that was regulated, and harboured two potential *mir-1* binding sites in the 3' UTR
309 (Figure 3F, Supplemental Figure 3C). Moreover, *vha-13* RNAi (*vha-13i*) significantly
310 compromised the motility of *mir-1*;Q35 strains in the RNAi screens (Figure 2C), which
311 we further confirmed through thrashing assays and the circle test (Figure 2E-G). *vha-13i*
312 also significantly reduced pharyngeal pumping and life span in the *mir-1*;Q35
313 background compared to *luci* RNAi controls (Figures 2H and I, Supplemental Tables 1
314 and 2), yet had relatively minor effects on the motility of N2;Q35 itself (Supplemental
315 Figure 2F). We therefore focused on *vha-13* as a promising candidate to pursue in
316 depth for regulatory interactions with miR-1.

317 We first characterized the expression pattern of *3xFlag::mNeonGreen::vha-13(syb586)* in more detail. The fusion protein was strongly expressed in the excretory
318 cell, canal, hypodermis, as well as gut (Figure 3B). In the hypodermis
319 *3xFlag::mNeonGreen::VHA-13* was localized in discrete foci (Figure 3B, Supplemental
320 Figure 3D). Notably, *3xFlag::mNeonGreen::VHA-13* also resided in miR-1 expressing
321 tissues of body wall muscle, sex muscles and pharynx, where it was more weakly
322 expressed. Within muscle cells, VHA-13 localized to dense bodies (analogous to
323 vertebrate Z disks) and intervening cytosol (Figure 3B, Supplemental Figure 3D).

325 Because *mir-1* is expressed in muscle tissues, we focused on quantifying the
326 expression of *vha-13* in these tissues. Strikingly, we observed that VHA-13 levels were
327 upregulated in the pharyngeal isthmus of *mir-1* mutants (Figure 3C and D,
328 Supplemental Table 7), while conversely, overexpression of the *mir-1* transgene
329 decreased levels in this tissue relative to wild-type (Figure 3E, Supplemental Table 7).
330 To further investigate whether miR-1 directly regulates *vha-13*, we altered two
331 predicted miR-1 binding sites (BS) in the 3'UTR (Figure 3F). We first mutated miR-1
332 binding site 1 (*vha-13* BS1 (*syb504*), at position 188-195 of *vha-13* 3'UTR), and then
333 additionally miR-1 binding site 2 (*vha-13* BS2 (*syb2180*), at position 253-58 of *vha-13*
334 3'UTR) in the endogenously-tagged *vha-13*(*syb586*) strain. When only BS1 was
335 mutated, we still saw residual regulation of VHA-13 by miR-1 (Supplemental Figure
336 3E, Supplemental Table 7). Mutating both miR-1 binding sites (BS1,2: MUT2),
337 however, de-repressed VHA-13 levels in the isthmus in the WT background (Figure
338 3G). In double mutants containing both *mir-1* and *vha-13* BS1,2 mutations, no clear
339 regulation of *vha-13* expression was observed compared to the BS1,2 mutations alone
340 (Figure 3G), suggesting that miR-1 modulates pharyngeal *vha-13* expression through
341 both potential miR-1 BS sites.

342 We next sought to characterize *vha-13* regulation in the body wall muscle.
343 However, it was not possible to accurately measure expression in this tissue using the
344 *3xFlag::mNeonGreen::vha-13* strain due to the high expression levels in the adjacent
345 hypodermis and gut. We therefore generated transgenic worms expressing flag-
346 tagged *vha-13* containing its endogenous 3'UTR (*3xFlag::vha-13::vha-13* 3'UTR)
347 under control of the muscle-specific *myo-3* promoter. Consistent with results seen in
348 pharyngeal muscle, *vha-13* protein levels in the body wall muscle were also
349 upregulated in *mir-1* mutants compared to WT, as measured by Western blots (Figure
350 3H and I). Exchanging the *vha-13* 3'UTR with the *unc-54* 3'UTR lacking miR-1 binding
351 sites (*vha-13::unc-54* 3'UTR) blunted regulation by miR-1 (Figure 3H and I), indicating
352 that *vha-13* is repressed by miR-1 via its 3'UTR in both body wall and pharyngeal
353 muscle.

354



355

356 **Figure 3. miR-1 directly regulates vha-13 via its 3'UTR in muscle tissue.**

357 **(A)** RT-qPCR of *vha-5*, *vha-10*, *vha-13* and *vha-19*, as well as *daf-16* and *hlh-30* mRNA levels in WT
358 (N2) and *mir-1*(*gk276*) mutants on day 4 of adulthood. Mean \pm SEM, N=3, one way ANOVA, **, p<0.01,
359 ***, p<0.001.

360 **(B)** Expression pattern of endogenously tagged *3xFlag::mNeonGreen::vha-13* in pharynx, excretory cell
361 and canal, gut, vulva muscle (vum), hypodermis, muscle (arrowhead indicates dense body).

362 **(C)** Confocal images of the head region in worms carrying endogenously tagged
363 *3xFlag::mNeonGreen::vha-13* in late L4 *mir-1* and WT animals at 25°C. Red rectangle highlights the
364 area of *vha-13* expression in the isthmus used for determination of mNeonGreen intensity. **(D)**
365 Quantification of fluorescent intensity of *3xFlag::mNeonGreen::vha-13* expression in the isthmus of
366 indicated genotypes (as shown in **(C)**) in late L4 larvae at 25°C. Mean \pm SEM of N=5, t-test, **, p<0.01.
367 **(E)** Quantification of fluorescent intensity of *3xFlag::mNeonGreen::vha-13* expression in the isthmus of
368 N2; *mir-1* transgenic overexpression strain in late L4 larvae at 25°C. Transgenic worms (*mir-1*
369 transgene) were compared to non-transgenic segregants (N2) of the same strain. Mean \pm SEM of N=4,
370 t-test, ***, p<0.001.
371 **(F)** Graphic showing the 3'UTR of endogenously tagged *3xFlag::mNeonGreen::vha-13*. *vha-13* wt: *vha-*
372 *13* wild-type 3'UTR. *vha-13* MUT1: one miR-1 binding site (BS) is mutated. *vha-13* MUT2: both miR-1
373 BSs are mutated. *unc-54*: the *vha-13* 3'UTR is substituted by *unc-54* 3'UTR. Nucleotide sequence of
374 mutated miR-1 binding sites are shown below WT.
375 **(G)** Quantification of fluorescence intensity in the isthmus of L4 larvae with endogenously tagged
376 *3xFlag::mNeonGreen::vha-13* *vha-13* MUT2 3'UTR in relation to *vha-13* wt 3'UTR, in N2 and *mir-*
377 *1*(*gk276*) mutant backgrounds at 25°C, using confocal imaging. Mean \pm SEM of N=3, one representative
378 experiment, one-way ANOVA, ****, p<0.0001, ns not significant.
379 **(H)** Western blot image of late L4 WT and *mir-1* mutants expressing transgenic flag-tagged *vha-13* in
380 body wall muscle (*myo-3p::vha-13*) with either the *unc-54* 3'UTR (labelled in red), which lacks miR-1
381 BSs, or the wt *vha-13* 3'UTR which contains the two miR-1 BSs (labelled in black), immunoblotted with
382 anti-Flag and anti-Histone H3 antibodies. Histone H3 loading control is shown below. Biological
383 replicates (N=3) separated by dashed lines. **(I)** Quantification of Western blot shown in **(H)**, with flag-tag
384 intensity normalized to histone H3 loading control, mean \pm SEM of N=3, one-way ANOVA, ***, p<0.001,
385 ns, not significant.
386 **(J)** Quantification of aggregates in Q35 worms expressing transgenic *vha-13* in the body wall muscle
387 (*myo-3p::vha-13*;Q35) or non-transgenic segregants (Q35) of the same strain. 25 worms per genotype,
388 mean \pm SEM of one representative experiment, N=4, t-test, ***, p<0.001.
389 **(K)** Motility of Q35 worms expressing transgenic *vha-13* in the body wall muscle (*myo-3p::vha-13*;Q35)
390 or non-transgenic segregants (Q35) of the same strain in circle test. Mean \pm SEM. One experiment of
391 N=2, t-test, ***, p<0.001.
392 **(L)** Pharyngeal pumping rate of *myo-3p::vha-13*;Q35 and Q35 non-transgenic segregants of the same
393 strain. One representative experiment of N=4, mean \pm SEM, t-test, ***, p<0.001.
394

395 Since *mir-1* mutation resulted in *vha-13* upregulation, we asked whether *vha-13*
396 overexpression was sufficient to yield phenotypes similar to *mir-1* mutants. In accord
397 with this idea, overexpressing *vha-13* in the muscle of Q35 worms significantly reduced
398 aggregate number, improved motility, and enhanced pharyngeal pumping ability
399 (Figure 3J-L, Supplemental Figure 3F, Supplemental Table 2). It also significantly
400 increased the life span of Q35 animals compared to non-transgenic controls in 2/4
401 experiments (Supplemental Figure G, Supplemental Table 1). Altogether these data

402 suggest that miR-1 and VHA-13 work in the same regulatory pathway to influence
403 muscle physiology.

404

405 **miR-1 regulates *h/h-30/TFEB* transcription factor**


406 Our RT-PCR experiments indicated that miR-1 also regulates mRNA levels *h/h-*
407 *30/TFEB* and *daf-16/FOXO* transcription factors (Figure 3A). These factors modestly
408 affected motility in the circle test (Figure 2F), and we wondered if regulation extended
409 to the protein level. When we examined endogenously tagged *h/h-30*, we saw no
410 obvious regulation of protein expression levels when measured by fluorescence
411 intensity in the pharynx (Supplemental Figure 4A and B, Supplemental Table 7).
412 Surprisingly, however, we observed that nuclear localization of HLH-30::mNeonGreen
413 in the hypodermis of day 4 adults grown at 25°C was significantly increased in the *mir-*
414 *1* background (Figure 4A and 4B). This finding suggests that miR-1, either directly or
415 indirectly, regulates HLH-30 in distal tissues.

416

417 **miR-1 affects lysosomal biogenesis**

418 As the v-ATPase is an integral component of the lysosome, we asked whether
419 miR-1 generally affects lysosomal structure and function. To test this idea, we first used
420 a *Imp-1p::Imp-1::gfp* reporter strain. LMP-1 protein localizes to the membrane of
421 lysosomes and is a marker for lysosomal biogenesis (Hermann et al., 2005). LMP-1
422 protein levels were significantly increased in *mir-1* mutants compared to WT control,
423 as measured by Western blot analysis (Figure 4C and D). The v-ATPase hydrolyses
424 ATP to pump protons across the membrane, resulting in acidification of the lysosome
425 lumen (Beyenbach & Wieczorek, 2006). We therefore asked whether *mir-1* mutants
426 affect the number of acidified lysosomes. Using Lysotracker Red, a dye that targets
427 acidic membranous structures such as lysosomes (Chazotte, 2011), we observed an
428 increase in the number of acidified puncta in *mir-1* mutants at day 4 of adulthood
429 (Figure 4E and F). Due to technical limitations, lysotracker staining could only be
430 observed in the worm intestine. This result leaves open the question as to whether
431 lysosomes are also regulated in the muscle and whether *mir-1*, being expressed in
432 muscle tissue, might have a cell non-autonomous effect. Nonetheless, the overall
433 increase in lysosome biogenesis is consistent with the upregulation of lysosomal

434 components, such as the v-ATPase subunits, and a possible cause of miR-1-
 435 dependent regulation of proteostasis.



436
 437 **Figure 4. *mir-1* mutation enhances lysosomal biogenesis and acidification.**
 438 **(A)** Fluorescent image comparing HLH-30::mNeonGreen nuclear localization in the hypodermis of the
 439 *mir-1*(*gk276*) and WT (*N2*) backgrounds. **(B)** Quantitation of nuclear localization in (A). Violin plot, mean
 440 \pm SEM of one representative experiment of N=3, t-test, ****, p<0.0001.
 441 **(C)** Western blot of LMP-1::GFP in WT and *mir-1* mutants at the L4 stage, immunoblotted with anti-GFP
 442 or anti- α -tubulin antibodies. Biological replicates (N=3) separated by dashed lines. **(D)** Quantification of

443 the Western blot in **(C)**, normalized to α -tubulin loading control. N=3 BR, line and error bars indicate
444 mean \pm SEM, t-test, **, p<0.01.
445 **(E)** Representative images of lysotracker staining in WT and *mir-1* mutants at day 4 of adulthood at
446 25°C. **(F)** Quantification of lysotracker images using a predefined squared area approximately spanning
447 the second to fourth gut cell. Quantification was performed using Image J. N=3 BR, line and error bars
448 indicate mean \pm SEM of combined experiments, t-test, *, p<0.05.
449 **(G)** Working model. miR-1 normally limits proteoprotective pathways, downregulating the expression of
450 *vha-13*, other v-ATPases and factors by binding miR-1 binding site(s) in the 3'UTR (miR-1 BS) of the
451 corresponding mRNA (WT, proteotoxic stress). Loss of miR-1 under proteotoxic conditions results in
452 free *vha-13* mRNA, higher VAH-13 protein levels, and elevated lysosomal activity (LMP-1). Nuclear
453 localization of HLH-30/TFEB, a master regulator of lysosome biogenesis is also enhanced, collectively
454 resulting in improved mid-life muscle motility, pharyngeal pumping, and organismal longevity under
455 proteotoxic stress conditions.

456

457

458 **Discussion**

459 Striated muscle is one of the most highly ordered tissues in the body, with
460 molecular components organized in a lattice of contractile elements and attachments.
461 This molecular apparatus is exposed to high energy and force during contraction,
462 inflicting molecular damage requiring constant repair. Further, muscle is subject to
463 growth, metabolic, and stress signalling pathways as well as neural inputs that also
464 promote remodelling. Underlying muscle plasticity is the fine-tuned control of
465 proteostasis, including protein synthesis, folding, trafficking and turnover, which must
466 be precisely orchestrated to maintain muscle structure and function (Demontis et al.,
467 2013). A decline in these processes during aging leads to diminished muscle
468 performance and frailty, yet it remains elusive how various aspects of muscle
469 proteostasis are coordinated.

470 In this work, we discovered that the muscle enriched microRNA miR-1 plays an
471 important role in regulating muscle homeostasis via vacuolar ATPase function. Loss
472 of *mir-1* ameliorates age-related decline in motility induced by models of aggregate-
473 prone polyQ35. By inference, *mir-1* normally limits proteoprotective pathways.
474 Computational and proteomic screens identified v-ATPase subunits as highly enriched
475 targets of miR-1 regulation, suggestive of coordinate regulation, and whose
476 downregulation reduced proteoprotection. Expression studies confirmed that several
477 subunits (e.g., *vha-5*, *vha-10*, *vha-13*, *vha-19*) showed miR-1 dependent regulation. In

478 particular, we demonstrated that *vha-13* expression is downregulated by miR-1 in
479 muscle tissues via two distinct binding sites in its 3'UTR. Moreover, VHA-13 links
480 miR-1 with muscle homeostasis, since *vha-13* downregulation abolished the improved
481 mid-life motility, pharyngeal pumping and life span of *mir-1*;Q35 strains, while *vha-13*
482 overexpression was sufficient to enhance these properties, similar to *mir-1* mutation.
483 In accord with our findings, immunoprecipitation and sequencing of microRNA
484 complexes revealed a number of v-ATPase subunit mRNAs, including *vha-13*, *vha-4*,
485 *vha-10*, and *vha-17* as physically associated with *C. elegans* miR-1 (Grosswendt et
486 al., 2014). Interestingly, mammalian homolog of VHA-13, ATP6V1A, as well as several
487 other v-ATPase subunits (Stark, Brennecke, Bushati, Russell, & Cohen, 2005),
488 harbour predicted miR-1 binding sites, suggesting that this regulatory module could be
489 conserved in evolution.

490 The v-ATPase is a multisubunit enzyme which acidifies the endolysosomal
491 lumen to control a plethora of cellular activities. Acidification regulates protein
492 trafficking, endocytic recycling, synaptic vesicle loading, and autophagy, as well as the
493 activity of multiple acid hydrolases and nutrient and ion transporters. Moreover, the v-
494 ATPase itself serves as a docking site for regulating mTOR and AMPK complexes and
495 affects metabolism (Settembre, Fraldi, Medina, & Ballabio, 2013; Zhang et al., 2014).
496 Our studies highlight the importance of v-ATPase activity to muscle performance. A
497 handful of studies ascribe a role for the v-ATPase in muscle. In mammalian
498 cardiomyocytes, lipid loading inhibits the v-ATPase, leading to a decline in contractile
499 function that could contribute to muscle deficits in diabetes (Wang et al., 2020). Lesions
500 in VMA21 that disrupt v-ATPase assembly have also been shown to cause myopathies
501 (Dowling, Moore, Kalimo, & Minassian, 2015). Conceivably the v-ATPase could play
502 an important role in protein turnover and remodeling of muscle structure but could also
503 impact muscle homeostasis through metabolic wiring or protein trafficking.

504 Surprisingly we also found that some *mir-1* phenotypes were not strictly limited
505 to muscle, since we observed a global increase in levels of lysosomal LMP-1::GFP in
506 Western blots, increased lysosomal acidification in the intestine, as well as enhanced
507 nuclear localization of HLH-30/TFEB in the hypodermis. Given that *mir-1* is muscle-
508 expressed, this observation could suggest cell non-autonomous regulation of
509 lysosomal biogenesis and associated activities by *mir-1*, acting either directly or
510 indirectly. Conceivably, miR-1 is secreted from muscle to affect physiology in other

511 tissues. In mammals miR-1 has been identified as a circulating microRNA found in
512 serum exosomes upon exercise stress or cardiac infarction, suggesting it could act
513 systemically (Cheng et al., 2019) (D'Souza et al., 2018). In this light, it is intriguing that
514 the v-ATPase itself is implicated in exosomal activity activity (Liegeois, Benedetto,
515 Garnier, Schwab, & Labouesse, 2006). Alternately, *mir-1* could act indirectly through
516 production of a myokine that affects distal tissues.

517 miR-1 has been implicated in regulating a number of targets and physiologic
518 processes. In mammals, miR-1 and its homolog miR-133 are essential to cardiac
519 development and function, where they have been shown to regulate Notch ligand
520 DII-1, the GTPase dynamin 2 (DNM2), FZD7 (Frizzled-7), and FRS2 (fibroblast growth
521 factor receptor substrate 2) as targets (Ivey et al., 2008; Liu et al., 2011; Mitchelson &
522 Qin, 2015). Surprisingly knockout of mammalian *mir1/mir133* specifically in muscle has
523 little overt effect on muscle structure, but rather regulates the developmental transition
524 from glycolytic to oxidative metabolism via the MEF-2/Dlk1-Dio3 axis, affecting running
525 endurance (Wust et al., 2018). Similarly, *C. elegans* miR-1 regulates *mef-2*, in this case
526 affecting retrograde signalling at the neuromuscular junction (Simon et al., 2008). We
527 also observed that animals lacking *mir-1* have little overt change in muscle structure
528 or function alone, though we saw upregulation of a number of muscle proteins and
529 downregulation of mitochondrial proteins in our proteomic analysis. Indeed, most
530 microRNA knockouts do not lead to observable phenotypes in *C. elegans* (Miska et al.,
531 2007), suggesting that microRNAs often work redundantly or in response to stress to
532 fine tune gene expression.

533 Recently Pocock and colleagues reported that miR-1 downregulates the rab
534 GTPAse TBC-7/TBC1D15, thereby promoting autophagic flux in worms and human
535 cells (Nehammer et al., 2019). In *C. elegans* they observed that *mir-1(+)* ameliorates
536 polyQ40 proteotoxicity, seemingly contradicting our results. Other studies suggest that
537 mammalian *mir-1* can either promote or inhibit autophagy, dependent on context
538 (Ejlerskov, Rubinsztein, & Pocock, 2020; Hua, Zhu, & Wei, 2018; Xu, Cao, Zhang,
539 Zhang, & Yue, 2020). Whether miR-1 is proteoprotective or limits proteoprotection in
540 *C. elegans* could hinge on many factors. We used polyQ35, Pocock et al used
541 polyQ40; these species differ in the effect on aggregation and motility (Morley et al.,
542 2002). For motility assays, we assessed all animals that were alive, they excluded
543 paralyzed animals. We performed motility assays on day 8, they performed them

544 earlier in adulthood. Because microRNAs generally fine tune regulation, and often work
545 in feedback circuits, their impact on physiology can be subtle, and small differences in
546 culture conditions, genetic background, assay method, or metabolic state could give
547 rise to divergent outcomes.

548 Among the putative miR-1 targets that we identified in *C. elegans* are the pro-
549 longevity transcription factors DAF-16/FOXO and HLH-30/TFEB, which regulate
550 lysosome biogenesis, proteostasis, and metabolism, and act in insulin/IGF and mTOR
551 signalling pathways (Lin et al., 2018; O'Rourke & Ruvkun, 2013; Settembre et al.,
552 2011). *mir-1* mutation led to an upregulation of their mRNA during adulthood and
553 enhanced nuclear localization of HLH-30. Further RNAi knockdown of these factors
554 modestly diminished the motility improvement of *mir-1* mutants in the circle test,
555 consistent with roles in a miR-1 signalling pathway. Whether these transcription factors
556 are direct targets of miR-1 regulation remains to be seen. Notably, miR-1 predicted
557 targets also include pro-ageing components of mTOR signalling such as *let-363*/mTOR
558 and *raga-1*/RagA (targets.org), which also regulate the activity of these
559 transcription factors. Hence the balance or timing of pro- and anti-ageing factors could
560 also differentially influence the physiologic phenotype at a systemic level. Interestingly,
561 VHA-13/ATP6VIA subunit has been shown to regulate mTOR lysosomal recruitment
562 and activity (Chung et al., 2019) and mTOR signalling regulates the activity of TFEB
563 at the lysosomal surface (Settembre et al., 2013). Upregulation of v-ATPase activity is
564 also associated with the clearance of oxidized protein and rejuvenation of the *C.*
565 *elegans* germline (Bohnert & Kenyon, 2017). Thus, in the future it will be interesting to
566 further unravel the miR-1 molecular circuitry surrounding lysosomal function and
567 proteostasis, and see whether miR-1 similarly regulates v-ATPase function in humans.

568

569

570 **Materials and Methods**

571 **C. elegans strains and culture**

572 *C. elegans* strains were maintained at 20°C on nematode growth medium
573 (NGM) plates seeded with a lawn of *E. coli* strain OP50, unless noted otherwise.

574

575 N2 Bristol (wild-type) CGC

576 AA2508, *mir-1(gk276)* I

577 AA4575, *mir-1(dh1111)* I

578 AM140, *rmls132[unc-54p::Q35::YFP]* I

579 AA4403, *mir-1(gk276); rmls132[unc-54p::Q35::YFP]* I

580 AA4577, *mir-1(dh1111) rmls132[unc-54p::Q35::YFP]* I

581 AA3275, N2; *dhEx965[mir-1p::mir-1, myo-2p::mCherry]*

582 AA4810, *mir-1(gk276)* I; *rmls132[unc-54p::Q35::YFP]; dhEx965[mir-1p::mir-1, myo-2p::mCherry]*

583 AA4865, N2; *dhEx1206[myo3p::flag::HA::mCherry::vha-13cDNA::unc-54 3'UTR, myo-2p::GFP]*

584 AA4866, *mir-1(gk276)* I; *dhEx1206[myo-3p::flag::HA::mCherry::vha-13cDNA::unc-54 3'UTR, myo-2p::GFP]*

585 AA5067, N2; *dhEx1207[myo-3p::flag::HA::mCherry::vha-13cDNA::vha-13 3'UTR, myo-2p::GFP]*

586 AA5068, *mir-1(gk276)* I; *dhEx1207[myo-3p::flag::HA::mCherry::vha-13cDNA::vha-13 3'UTR, myo-2p::GFP]*

587 PHX586, *vha-13(syb586[3xFlag::mNeonGreen::vha-13])* V

588 AA4813, *mir-1(gk276)* I; *vha-13(syb586[3xFlag::mNeonGreen::vha-13])* V

589 AA4850, *vha-13(syb586[3xFlag::mNeonGreen::vha-13])* V; *dhEx965[mir-1p::mir-1, myo-2p::mCherry]*

590 PHX587, *vha-13(syb587,syb504[3xFlag::mNeonGreen::vha-13 miR-1 BS1 mutated])*

591 V. Also named in the text *vha-13 MUT1*.

592 AA4184, *mir-1(gk276)* I; *vha-13(syb587,syb504[3xFlag::mNeonGreen::vha-13 miR-1 BS1 mutated])* V

593 PHX2180, *vha-13(syb2180,syb587,syb504[3xFlag::mNeonGreen::vha-13 miR-1 BS1,2 mutated])* V. Also named in the text *vha-13 MUT2*.

594 AA5123, *mir-1(gk276)* I; *vha-13(syb2180,syb587,syb504[3xFlag::mNeonGreen::vha-13 miR-1 BS,2 mutated])* V

604 PHX1093, *vha-5(syb1093[3xFlag::mNeonGreen::vha-5])* IV
605 AA5069, *mir-1(gk276)* I; *vha-5(syb1093[3xFlag::mNeonGreen::vha-5])* IV
606 PHX809, *hlh-30(syb809[hlh-30::mNeonGreen])* IV
607 AA5195, *mir-1(gk276)* I; *hlh-30(syb809[hlh-30::mNeonGreen])* IV
608

609 Molecular cloning

610 All restriction digest reactions were performed with enzymes provided by NEB
611 according to the user's manual. T4 DNA Ligase (NEB) was used for ligation reactions.
612 Chemically competent DH5 α *Escherichia coli* (LifeTechnologies) was used for
613 transformation following the manufacturer's instructions. QIAprep Miniprep or Midiprep
614 Kits (Qiagen) were used for plasmid purification. Cloning was verified by PCR followed
615 by gel electrophoresis and sequencing.

616 To make the rescuing *mir-1* transgene, primer pair "celmir1fwd2/rvs2" (Table
617 S8) was used to insert the *mir-1* coding region into vector L3781 downstream of *gfp*.
618 The *mir-1* promoter was then cloned 5' to *gfp* using the primer pair "m1p fwd/rvs" (Table
619 S8). To make muscle expressed *vha-13* constructs, the *vha-13* cDNA was amplified
620 with Kpn1 overhangs using primers *vha-13* fwd/rvs (Table S8) and cloned into vector
621 pDESTR4-R3 to give *myo3p::flag::HA::mCherry::vha-13cDNA::unc-54* 3'UTR. The
622 *unc-54* 3'UTR was excised with Not1/BgII and replaced with the *vha-13* 3'UTR using
623 primers *vha-13U* fwd/rvs (Table S8) to generate *myo3p::flag::HA::mCherry::vha-*
624 *13cDNA::vha-13* 3'UTR.

625

626 Generation of transgenic worm strains

627 Transgenic worms containing extrachromosomal arrays were generated by
628 microinjection. To generate the ***myo3p::flag::HA::mCherry::vha-13cDNA::unc-54***
629 **3'UTR** strain, a mix of *myo3p::flag::HA::mCherry::vha-13cDNA::unc-54* 3'UTR DNA
630 (40ng/ μ l), *myo-2p::gfp* co-transformation marker (5 ng/ μ l plasmid pPD122.11) and
631 fill DNA (TOPO empty vector, 55 ng/ μ l) was injected into young N2 adults using an
632 Axio Imager Z1 microscope (Zeiss) with a manual micromanipulator (Narishige)
633 connected to a microinjector (FemtoJet 4x, Eppendorf). We obtained the strain
634 AA4865: N2; *dhEx1206[myo3p::flag::HA::mCherry::vha-13cDNA::unc-54* 3'UTR, *myo-*
635 *2p::gfp*], which was then used to cross the transgene into other genetic backgrounds.

636 A similar strategy was used to create AA5067, N2;
637 *dhEx1207[myo3p::flag::HA::mCherry::vha-13cDNA::vha-13 3'UTR, myo-2p::GFP]*.

638

639 The ***mir-1 transgene*** strain was generated by injection mix containing *mir-1p::mir-1* plasmid, *myo-2p::mCherry* co-transformation marker (5 ng/ μ l plasmid
640 pPD122.11) and fill DNA (L3781 empty vector). The resultant strain AA3275 (N2;
641 *dhEx965[mir-1p::mir-1, myo-2p::mCherry]*) was then used to cross the *dhEx965*
642 transgene to *mir-1(gk276); rmls132[p(unc-54) Q35::YFP]* to give *mir-1(gk276); rmls132[p(unc-54) Q35::YFP]; dhEx965[mir-1p::mir-1, myo-2p::mCherry]*, AA4810.
643 For transgenic worm strains, non-transgenic worms of the same strain were used as
644 controls.

645
646 The ***mir-1 deletion allele dh1111*** was generated using CRISPR/Cas9
647 mutagenesis. We designed CRISPR guides using the EnGen sgRNA Designer
648 (<https://sgRNA.neb.com/#!/sgRNA>), synthesized guides with the EnGen sgRNA synthesis
649 kit and analysed them by gel electrophoresis and tape station. We injected worms with
650 an injection mix containing Cas9 EnGen (NEB), 4 sgRNAs against *mir-1*
651 (AAGAAGTATGTAGAACGGGG, GTAAAGAAGTATGTAGAACG,
652 TATAGAGTAGAATTGAATCT, ATATAGAGTAGAATTGAATC), one sgRNA against
653 *dpy-10* (CGCTACCATAAGGCACCACG), KCl, Hepes pH 7.4 and water. Prior to
654 injection we incubated the mixture for 10 minutes at 37°C to allow activation of Cas9.
655 Following injection, we singled out worms with Dpy phenotype in the F1 generation
656 and genotyped them for *mir-1* deletion using *mir-1* genotyping primers (Supplemental
657 Table 8). We sequenced the PCR products of candidate worms with Sanger
658 sequencing and verified that the deletions resulted in loss of *mir-1* expression using
659 Taqman-based quantification of mature miRNA levels.

660
661 **Endogenous fluorescently tagged strains** were generated by tagging *vha-5*
662 or *vha-13* with 3xFLAG-mNeonGreen tag at the N-terminus using CRISPR–Cas9
663 (SunnyBiotech). The *vha-13* 3'UTR mutants BS1 and BS2 were generated using
664 CRISPR–Cas9, by further mutating one or both putative miR-1 binding sites in the
665 3'UTR of the endogenous FLAG-mNeonGreen-tagged *vha-13* gene (SunnyBiotech).
666 PHX809 *hhl-30::mNeonGreen* endogenously tagged *hhl-30* was generated by placing
667 *mNeonGreen* at the C-terminus using CRISPR–Cas9 (SunnyBiotech).

668

669 **Determination of progeny number**

670 Single worms were maintained on an NGM agar plate and transferred every day
671 until the reproductive period was complete. The number of F1 progeny per individual
672 worm was counted at the L4 or young adult stage. Experiments were repeated at least
673 three times.

674 **Quantitation of polyQ aggregates**

675 Whole-worm images of day 4 adults were taken with an Axiocam 506 mono
676 (Zeiss) camera using the 5x objective of a Zeiss Axio Imager Z1 microscope (20ms
677 exposure). Q35 aggregate numbers were evaluated from photos at 163%
678 magnification. Genotypes of the samples were blinded during the counting. Aggregates
679 were defined as discrete structures or puncta above background.

680

681 **Motility, thrashing and pumping behaviour**

682 To analyse worm motility by the circle test, 20 to 25 worms were placed in the
683 centre of a 6 cm agar plate with bacteria, marked with 1 cm circle on the bottom. After
684 a defined time period (1 or 30 minutes) the number of worms that left the circle were
685 counted. To determine thrashing rate, individual worms were transferred to M9 buffer
686 and the number of body bends in a 20 to 30 second interval was scored. Pharyngeal
687 pumping rates were measured by counting grinder contraction in the terminal bulb over
688 20 to 30 seconds. Genotypes were blinded during all experiments.

689

690 **CeleST Assay**

691 The *C. elegans* Swim Test (CeleST) assay was used to assess animal motility
692 while swimming; assays were conducted as described previously (Ibanez-Ventoso,
693 Herrera, Chen, Motto, & Driscoll, 2016; Restif et al., 2014). Four or five animals were
694 picked and placed into the swimming arena, which was a 50 μ l aliquot of M9 Buffer
695 inside a 10 mm pre-printed ring on the surface of a glass microscope slide (Thermo
696 Fisher Scientific). Images of the animals within the swim arena were acquired with a
697 LEICA MDG41 microscope at 1x magnification with a Leica DFC3000G camera. Image
698 sequences of 30 seconds in duration were captured at a rate of ~16 frames per second.
699 The established CeleST software was used to process the image sequences and
700 extract 8 measures that are descriptive of *C. elegans* swim motility. As not all images
701 in a sequence are always successfully processed by the CeleST software, animals for
702 which fewer than 80% of frames were valid were excluded from the analysis. For each

703 measure, single measurements that did not fit within the range of normally observed
704 values were deemed outliers and also excluded from the analysis. Unpaired Student's
705 t-test was used to test for statistical significance between two strains at adult day 4 and
706 day 8.

707

708 **Life span and heat stress experiments**

709 Life span experiments were performed as described (Gerisch et al., 2007). Day
710 0 corresponds to the L4 stage. Life spans were determined by scoring a population of
711 100 to 120 worms per genotype every day or every other day. Worms that exploded,
712 had internal hatch or left the plate were censored. Heat stress experiments were
713 performed at 35°C (Gerisch et al., 2007). Day 1 adult worms were transferred onto pre-
714 heated (35°C) plates 6 cm plates seeded with OP50. Worms were kept at 35°C and
715 scored every hour for live versus dead. Experiments were repeated at least three
716 times. Data were analysed with Microsoft Excel 16.12 and GraphPad Prism 7
717 Software. *P*-values were calculated using the Log-rank (Mantel-Cox) test to compare
718 two independent populations.

719

720 **RNAi Treatment**

721 Worms were grown from L4 onwards unless mentioned otherwise on *E. coli*
722 HT115 (DE3) bacteria expressing dsRNA of the target gene under the control of an
723 IPTG-inducible promotor. RNAi colonies were grown overnight at 37°C in Luria Broth
724 with 50 µg/ml Ampicillin and 10 µg/ml tetracycline. The cultures were spun down at
725 4,000 rpm at 4°C for 10 minutes. 500 µl of one-fold concentrated culture was seeded
726 onto NGM plates containing 1 M isopropyl β-D-1-thiogalactopyranoside (IPTG) to
727 induce dsRNA expression. RNAi clones were selected from the Ahringer or Vidal
728 library (Kamath & Ahringer, 2003; Rual et al., 2004). Clone identity was confirmed by
729 sequencing. Bacteria containing luciferase were used as control.

730

731 **RNAi screen for *mir-1* suppressors**

732 *mir-1(gk276)* Q35 worms were grown from L4 on RNAi of the candidates
733 identified in the bioinformatic or proteomic screen. Worms were maintained in the
734 presence of FUDR till day 8 of adulthood. The circle test was performed as described
735 above. The number of worms that left the circle was determined after 1 minute.
736 Selected candidates identified in the circle test were examined in the body bending
737 assay (see above). The effect of selected candidate RNAi clones was additionally

738 tested on polyQ35 in the wild-type background as counter screen. For this experiment
739 worms were grown till day 5 of adulthood. Motility assays were performed on day 5 of
740 adulthood because Q35 wild-type worms were less motile than the *mir-1(gk276)* Q35
741 and were largely paralyzed by day 8.

742

743 **RNA extraction and real-time qPCR analysis**

744 Worm populations (ca. 500 animals) were harvested on day 4 of adulthood and
745 washed twice in cold M9. Worm pellets were taken up in 700 µl QIAzol reagent
746 (Qiagen) and snap frozen in liquid nitrogen. Samples were subjected to 4 freeze/thaw
747 cycles and homogenized with 1.0 mm zirconia/silica beads (Fisher Scientific) in a
748 Tissue Lyser LT (Qiagen) for 15 min at full speed. After homogenization, 600µl
749 supernatant was transferred to fresh tubes and 120 µl chloroform were added to each
750 tube. Components were mixed by vortexing and incubated for 2 min at room
751 temperature. After 15 min centrifugation at 12,000 g 4°C, the aqueous phase was
752 collected for total RNA extraction using the RNeasy or miRNeasy Mini Kit (Qiagen)
753 according to manufacturer's instructions. RNA quantity and quality were determined
754 on a NanoDrop 2000c (PeqLab) and cDNA was prepared using the iScript cDNA
755 Synthesis Kit (BioRad). To quantify RNA expression, we used the Power SYBR Green
756 Master Mix (Applied Biosystems) on a ViiA 7 Real-Time PCR system (Applied
757 Biosystems). Four technical replicates were pipetted on a 384-well plate using the
758 JANUS automated workstation (PerkinElmer). Expression of target RNA was
759 calculated from comparative CT values, normalized to *ama-1* or *cdc-42* as internal
760 controls using the corresponding ViiA7 software. All unpublished primers were
761 validated by determination of their standard curves and melting properties. For
762 quantification of *mir-1* we used Taqman probes from LifeTechnologies/ThermoFisher
763 Scientific (Assay ID 000385) and normalized to expression of U18 as measured by
764 Taqman probes from LifeTechnologies/ThermoFisher Scientific (Assay ID 001764).
765 We used N=4 independent biological replicates, and four technical replicates for every
766 biological sample (for primers, refer to Supplementary Table 8).

767

768 **Western blot analysis**

769 For Western blot analysis synchronized young adult or gravid day 1 adult worms
770 were picked into Eppendorf tubes containing M9, snap frozen in liquid nitrogen and
771 lysed in 4x SDS sample buffer (Thermo Fisher) containing 50 mM DTT. After boiling

772 and sonication, equal volumes were subjected to reducing SDS-PAGE and transferred
773 to nitrocellulose membranes. The membranes were then blocked for two hours at room
774 temperature in 5% milk in Tris-buffered Saline and Tween20 (TBST) and probed with
775 the primary antibodies in TBST with 5% milk overnight at 4 °C. Specific secondary
776 antibodies (mouse or rabbit) were used at a concentration of 1:5000 in TBST with 5%
777 milk at room temperature for 2 hours. The membranes were developed with Western
778 Lightening Plus- Enhanced Chemiluminescence Substrate (PerkinElmer). Bands were
779 detected on a ChemiDoc MP Imaging System (BioRad) and the intensity quantified
780 using the corresponding Image Lab software (BioRad). The following antibodies were
781 used: anti-GFP (JL-8 Living Colors, mouse monoclonal), anti-Histone H3 (ab1791
782 Abcam, rabbit polyclonal), anti- α -Tubulin (T6199 Sigma, mouse monoclonal), anti-
783 FLAG (F1804 Sigma, mouse monoclonal), anti-mouse IgG (G-21040 Invitrogen, goat
784 polyclonal coupled with horseradish peroxidase), anti-rabbit IgG (G-21234 Invitrogen,
785 goat polyclonal coupled with horseradish peroxidase).

786

787 **Proteomic analysis**

788 For **sample collection and preparation**, day 1 N2 and *mir-1(gk276)* worms
789 were synchronized by egg laying, and $n \geq 5000$ worms per genotype were collected in
790 M9. Samples were washed three times in M9 and directly frozen in liquid nitrogen and
791 stored at –80 °C. 5 independent biological replicates of each genotype were collected
792 for further analyses. For **protein extraction** samples were thawed and boiled in lysis
793 buffer (100 mM Tris-HCl, 6 M guanidinium chloride, 10 mM Tris(2-
794 carboxyethyl)phosphine hydrochloride, 40 mM 2-Chloroacetamide) for 10 min, lysed
795 at high performance with a Bioruptor Plus sonicator (Diagenode) using 10 cycles of 30
796 s sonication intervals. The samples were then boiled again, centrifuged at 20000g for
797 20 min, and diluted 1:10 in 20 mM Tris pH 8.3 / 10% acetonitrile (ACN). Protein
798 concentration was measured using BCA Protein Assays (Thermo Fisher). Samples
799 were then digested overnight with rLys-C (Promega), the peptides were cleaned on a
800 Supelco Visiprep SPE Vacuum Manifold (Sigma) using OASIS HLB Extraction
801 cartridges (Waters). The columns were conditioned twice with Methanol, equilibrated
802 twice with 0.1% formic acid, loaded with the sample, washed three times with 0.1%
803 formic acid and the peptides eluted with 60% ACN / 0.1% formic acid. The samples
804 were dried at 30°C for roughly 4 h in a Concentrator (Eppendorf) set for volatile
805 aqueous substances. The dried peptides were taken up in 0.1% formic acid and the

806 samples were analysed by the Max Planck Proteomic Core facility. **Mass**
807 **spectrometry** data acquisition, computational proteomic analysis and differential
808 expression analysis were performed as described (Tharyan et al., 2020). Upon
809 inspection of the numbers of quantified proteins and the raw proteomic data, two
810 replicates of N2 were excluded from further analysis.

811

812 **Microscopy and expression analysis**

813 For confocal microscopy *vha-13*, *vha-5* and *hlh-30* endogenously tagged with
814 mNeonGreen were synchronized via egg and maintained at 25°C to induce mild stress.
815 *hlh-30* worms were imaged as day 4 adults, while *vha-13* and *vha-5* worms as L4s,
816 because of high mNeonGreen background expression at day 4 adulthood. Worms
817 were anaesthetized with 40 µM sodium azide, mounted on slide with 2% agar pad and
818 imaged with a Leica TCS SP8 microscope equipped with HC PL APO CS2 63X/1.40
819 Oil and white light laser. Images were analysed using photoshop or Fiji software. To
820 quantitate acidic lysosomes, worms grown at 25°C were incubated 48 hours prior to
821 imaging with 2 µM Lysotracker Red DND-99 (Life Technologies). Worms were imaged
822 as day 4 adults as described above. Number of puncta in a predefined squared area
823 in the intestine (approximately spanning the second to fourth gut cell) were counted.

824

825 **Statistical Analysis**

826 The statistical tests performed in this study are indicated in figure legends and
827 in the method detail section. Data are represented as mean ± SEM or as individual
828 data points, as stated in the figure legends. Number of replicates and animals for each
829 experiment are enclosed in their respective figure legends.

830

831 **Data and Software Availability**

832 Accession Code: The mass spectrometry proteomics data have been
833 deposited to the ProteomeXchange Consortium via the PRIDE partner repository
834 (Perez-Riverol et al., 2019) with the dataset identifier PXD023544.

835

836 **References**

837

838 Andachi, Y., & Kohara, Y. (2016). A whole-mount *in situ* hybridization method for microRNA
839 detection in *Caenorhabditis elegans*. *RNA*, 22(7), 1099-1106.
840 doi:10.1261/rna.054239.115

841 Betel, D., Wilson, M., Gabow, A., Marks, D. S., & Sander, C. (2008). The microRNA.org
842 resource: targets and expression. *Nucleic Acids Res*, 36(Database issue), D149-153.
843 doi:10.1093/nar/gkm995

844 Beyenbach, K. W., & Wieczorek, H. (2006). The V-type H⁺ ATPase: molecular structure and
845 function, physiological roles and regulation. *J Exp Biol*, 209(Pt 4), 577-589.
846 doi:10.1242/jeb.02014

847 Bohnert, K. A., & Kenyon, C. (2017). A lysosomal switch triggers proteostasis renewal in the
848 immortal *C. elegans* germ lineage. *Nature*, 551(7682), 629-633.
849 doi:10.1038/nature24620

850 Brignull, H. R., Morley, J. F., Garcia, S. M., & Morimoto, R. I. (2006). Modeling polyglutamine
851 pathogenesis in *C. elegans*. *Methods Enzymol*, 412, 256-282. doi:10.1016/S0076-
852 6879(06)12016-9

853 Cartee, G. D., Hepple, R. T., Bamman, M. M., & Zierath, J. R. (2016). Exercise Promotes
854 Healthy Aging of Skeletal Muscle. *Cell Metab*, 23(6), 1034-1047.
855 doi:10.1016/j.cmet.2016.05.007

856 Chazotte, B. (2011). Labeling lysosomes in live cells with Lysotracker. *Cold Spring Harb
857 Protoc*, 2011(2), pdb prot5571. doi:10.1101/pdb.prot5571

858 Chen, X., Ba, Y., Ma, L., Cai, X., Yin, Y., Wang, K., . . . Zhang, C. Y. (2008). Characterization
859 of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other
860 diseases. *Cell Res*, 18(10), 997-1006. doi:10.1038/cr.2008.282

861 Cheng, M., Yang, J., Zhao, X., Zhang, E., Zeng, Q., Yu, Y., . . . Qin, G. (2019). Circulating
862 myocardial microRNAs from infarcted hearts are carried in exosomes and mobilise
863 bone marrow progenitor cells. *Nat Commun*, 10(1), 959. doi:10.1038/s41467-019-
864 08895-7

865 Chung, C. Y., Shin, H. R., Berdan, C. A., Ford, B., Ward, C. C., Olzmann, J. A., . . . Nomura,
866 D. K. (2019). Covalent targeting of the vacuolar H(+)-ATPase activates autophagy via
867 mTORC1 inhibition. *Nat Chem Biol*, 15(8), 776-785. doi:10.1038/s41589-019-0308-4

868 Cruz-Jentoft, A. J., Baeyens, J. P., Bauer, J. M., Boirie, Y., Cederholm, T., Landi, F., . . .
869 European Working Group on Sarcopenia in Older, P. (2010). Sarcopenia: European
870 consensus on definition and diagnosis: Report of the European Working Group on
871 Sarcopenia in Older People. *Age Ageing*, 39(4), 412-423. doi:10.1093/ageing/afq034

872 D'Souza, R. F., Woodhead, J. S. T., Zeng, N., Blenkiron, C., Merry, T. L., Cameron-Smith,
873 D., & Mitchell, C. J. (2018). Circulatory exosomal miRNA following intense exercise is
874 unrelated to muscle and plasma miRNA abundances. *Am J Physiol Endocrinol
875 Metab*, 315(4), E723-E733. doi:10.1152/ajpendo.00138.2018

876 Demontis, F., Piccirillo, R., Goldberg, A. L., & Perrimon, N. (2013). Mechanisms of skeletal
877 muscle aging: insights from *Drosophila* and mammalian models. *Dis Model Mech*,
878 6(6), 1339-1352. doi:10.1242/dmm.012559

879 Distefano, G., & Goodpaster, B. H. (2018). Effects of Exercise and Aging on Skeletal Muscle.
880 *Cold Spring Harb Perspect Med*, 8(3). doi:10.1101/cshperspect.a029785

881 Dowling, J. J., Moore, S. A., Kalimo, H., & Minassian, B. A. (2015). X-linked myopathy with
882 excessive autophagy: a failure of self-eating. *Acta Neuropathol*, 129(3), 383-390.
883 doi:10.1007/s00401-015-1393-4

884 Ejlerskov, P., Rubinsztein, D. C., & Pocock, R. (2020). IFNB/interferon-beta regulates
885 autophagy via a MIR1-TBC1D15-RAB7 pathway. *Autophagy*, 16(4), 767-769.
886 doi:10.1080/15548627.2020.1718384

887 Gerisch, B., Rottiers, V., Li, D., Motola, D. L., Cummins, C. L., Lehrach, H., . . . Antebi, A.
888 (2007). A bile acid-like steroid modulates *Caenorhabditis elegans* lifespan through
889 nuclear receptor signaling. *Proc Natl Acad Sci U S A*, 104(12), 5014-5019.
890 doi:10.1073/pnas.0700847104

891 Grosswendt, S., Filipchyk, A., Manzano, M., Klironomos, F., Schilling, M., Herzog, M., . . .
892 Rajewsky, N. (2014). Unambiguous identification of miRNA:target site interactions by
893 different types of ligation reactions. *Mol Cell*, 54(6), 1042-1054.
894 doi:10.1016/j.molcel.2014.03.049

895 Gu, S., & Kay, M. A. (2010). How do miRNAs mediate translational repression? *Silence*, 1(1),
896 11. doi:10.1186/1758-907X-1-11

897 Guo, Z., Maki, M., Ding, R., Yang, Y., Zhang, B., & Xiong, L. (2014). Genome-wide survey of
898 tissue-specific microRNA and transcription factor regulatory networks in 12 tissues.
899 *Sci Rep*, 4, 5150. doi:10.1038/srep05150

900 Hermann, G. J., Schroeder, L. K., Hieb, C. A., Kershner, A. M., Rabbitts, B. M., Fonarev,
901 P., . . . Priess, J. R. (2005). Genetic analysis of lysosomal trafficking in
902 *Caenorhabditis elegans*. *Mol Biol Cell*, 16(7), 3273-3288. doi:10.1091/mbc.e05-01-
903 0060

904 Herndon, L. A., Schmeissner, P. J., Dadaronek, J. M., Brown, P. A., Listner, K. M., Sakano,
905 Y., . . . Driscoll, M. (2002). Stochastic and genetic factors influence tissue-specific
906 decline in ageing *C. elegans*. *Nature*, 419(6909), 808-814. doi:10.1038/nature01135

907 Hua, L., Zhu, G., & Wei, J. (2018). MicroRNA-1 overexpression increases chemosensitivity of
908 non-small cell lung cancer cells by inhibiting autophagy related 3-mediated
909 autophagy. *Cell Biol Int*, 42(9), 1240-1249. doi:10.1002/cbin.10995

910 Ibanez-Ventoso, C., Herrera, C., Chen, E., Motto, D., & Driscoll, M. (2016). Automated
911 Analysis of *C. elegans* Swim Behavior Using CeleST Software. *J Vis Exp*(118).
912 doi:10.3791/54359

913 Ivey, K. N., Muth, A., Arnold, J., King, F. W., Yeh, R. F., Fish, J. E., . . . Srivastava, D. (2008).
914 MicroRNA regulation of cell lineages in mouse and human embryonic stem cells. *Cell*
915 *Stem Cell*, 2(3), 219-229. doi:10.1016/j.stem.2008.01.016

916 Jan, C. H., Friedman, R. C., Ruby, J. G., & Bartel, D. P. (2011). Formation, regulation and
917 evolution of *Caenorhabditis elegans* 3'UTRs. *Nature*, 469(7328), 97-101.
918 doi:10.1038/nature09616

919 Kamath, R. S., & Ahringer, J. (2003). Genome-wide RNAi screening in *Caenorhabditis*
920 *elegans*. *Methods*, 30(4), 313-321. doi:10.1016/s1046-2023(03)00050-1

921 Lall, S., Grun, D., Krek, A., Chen, K., Wang, Y. L., Dewey, C. N., . . . Rajewsky, N. (2006). A
922 genome-wide map of conserved microRNA targets in *C. elegans*. *Curr Biol*, 16(5),
923 460-471. doi:10.1016/j.cub.2006.01.050

924 Liegeois, S., Benedetto, A., Garnier, J. M., Schwab, Y., & Labouesse, M. (2006). The V0-
925 ATPase mediates apical secretion of exosomes containing Hedgehog-related
926 proteins in *Caenorhabditis elegans*. *J Cell Biol*, 173(6), 949-961.
927 doi:10.1083/jcb.200511072

928 Lin, X. X., Sen, I., Janssens, G. E., Zhou, X., Fonslow, B. R., Edgar, D., . . . Riedel, C. G.
929 (2018). DAF-16/FOXO and HLH-30/TFEB function as combinatorial transcription
930 factors to promote stress resistance and longevity. *Nat Commun*, 9(1), 4400.
931 doi:10.1038/s41467-018-06624-0

932 Liu, N., Bezprozvannaya, S., Shelton, J. M., Frisard, M. I., Hulver, M. W., McMillan, R. P., . . .
933 Olson, E. N. (2011). Mice lacking microRNA 133a develop dynamin 2-dependent
934 centronuclear myopathy. *J Clin Invest*, 121(8), 3258-3268. doi:10.1172/JCI46267

935 Martinez, N. J., Ow, M. C., Reece-Hoyes, J. S., Barrasa, M. I., Ambros, V. R., & Walhout, A.
936 J. (2008). Genome-scale spatiotemporal analysis of *Caenorhabditis elegans*
937 microRNA promoter activity. *Genome Res*, 18(12), 2005-2015.
938 doi:10.1101/gr.083055.108

939 Martinez, V. G., Javadi, C. S., Ngo, E., Ngo, L., Lagow, R. D., & Zhang, B. (2007). Age-
940 related changes in climbing behavior and neural circuit physiology in *Drosophila*. *Dev
941 Neurobiol*, 67(6), 778-791. doi:10.1002/dneu.20388

942 Miller, M. S., Lekkas, P., Braddock, J. M., Farman, G. P., Ballif, B. A., Irving, T. C., . . .
943 Vigoreaux, J. O. (2008). Aging enhances indirect flight muscle fiber performance yet
944 decreases flight ability in *Drosophila*. *Biophys J*, 95(5), 2391-2401.
945 doi:10.1529/biophysj.108.130005

946 Miska, E. A., Alvarez-Saavedra, E., Abbott, A. L., Lau, N. C., Hellman, A. B., McGonagle, S.
947 M., . . . Horvitz, H. R. (2007). Most *Caenorhabditis elegans* microRNAs are
948 individually not essential for development or viability. *PLoS Genet*, 3(12), e215.
949 doi:10.1371/journal.pgen.0030215

950 Mitchelson, K. R., & Qin, W. Y. (2015). Roles of the canonical myomiRs miR-1, -133 and -
951 206 in cell development and disease. *World J Biol Chem*, 6(3), 162-208.
952 doi:10.4331/wjbc.v6.i3.162

953 Morley, J. F., Brignull, H. R., Weyers, J. J., & Morimoto, R. I. (2002). The threshold for
954 polyglutamine-expansion protein aggregation and cellular toxicity is dynamic and
955 influenced by aging in *Caenorhabditis elegans*. *Proc Natl Acad Sci U S A*, 99(16),
956 10417-10422. doi:10.1073/pnas.152161099

957 Nair, K. S. (2005). Aging muscle. *Am J Clin Nutr*, 81(5), 953-963. doi:10.1093/ajcn/81.5.953

958 Nehammer, C., Ejlerskov, P., Gopal, S., Handley, A., Ng, L., Moreira, P., . . . Pocock, R.
959 (2019). Interferon-beta-induced miR-1 alleviates toxic protein accumulation by
960 controlling autophagy. *eLife*, 8. doi:10.7554/eLife.49930

961 O'Rourke, E. J., & Ruvkun, G. (2013). MXL-3 and HLH-30 transcriptionally link lipolysis and
962 autophagy to nutrient availability. *Nat Cell Biol*, 15(6), 668-676. doi:10.1038/ncb2741

963 Panwar, B., Omenn, G. S., & Guan, Y. (2017). miRmine: a database of human miRNA
964 expression profiles. *Bioinformatics*, 33(10), 1554-1560.
965 doi:10.1093/bioinformatics/btx019

966 Perez-Riverol, Y., Csordas, A., Bai, J., Bernal-Llinares, M., Hewapathirana, S., Kundu, D.
967 J., . . . Vizcaino, J. A. (2019). The PRIDE database and related tools and resources in
968 2019: improving support for quantification data. *Nucleic Acids Res*, 47(D1), D442-
969 D450. doi:10.1093/nar/gky1106

970 Pollock, R. D., O'Brien, K. A., Daniels, L. J., Nielsen, K. B., Rowlerson, A., Duggal, N. A., . . .
971 Harridge, S. D. R. (2018). Properties of the vastus lateralis muscle in relation to age
972 and physiological function in master cyclists aged 55-79 years. *Aging Cell*, 17(2).
973 doi:10.1111/acel.12735

974 Restif, C., Ibanez-Ventoso, C., Vora, M. M., Guo, S., Metaxas, D., & Driscoll, M. (2014).
975 CeleST: computer vision software for quantitative analysis of *C. elegans* swim
976 behavior reveals novel features of locomotion. *PLoS Comput Biol*, 10(7), e1003702.
977 doi:10.1371/journal.pcbi.1003702

978 Rual, J. F., Ceron, J., Koreth, J., Hao, T., Nicot, A. S., Hirozane-Kishikawa, T., . . . Vidal, M.
979 (2004). Toward improving *Caenorhabditis elegans* phenome mapping with an

980 ORFeome-based RNAi library. *Genome Res*, 14(10B), 2162-2168.
981 doi:10.1101/gr.2505604

982 Sardiello, M., Palmieri, M., di Ronza, A., Medina, D. L., Valenza, M., Gennarino, V. A., . . .
983 Ballabio, A. (2009). A gene network regulating lysosomal biogenesis and function.
984 *Science*, 325(5939), 473-477. doi:10.1126/science.1174447

985 Settembre, C., Di Malta, C., Polito, V. A., Garcia Arencibia, M., Vetrini, F., Erdin, S., . . .
986 Ballabio, A. (2011). TFEB links autophagy to lysosomal biogenesis. *Science*,
987 332(6036), 1429-1433. doi:10.1126/science.1204592

988 Settembre, C., Fraldi, A., Medina, D. L., & Ballabio, A. (2013). Signals from the lysosome: a
989 control centre for cellular clearance and energy metabolism. *Nat Rev Mol Cell Biol*,
990 14(5), 283-296. doi:10.1038/nrm3565

991 Simon, D. J., Madison, J. M., Conery, A. L., Thompson-Peer, K. L., Soskis, M., Ruvkun, G.
992 B., . . . Kim, J. K. (2008). The microRNA miR-1 regulates a MEF-2-dependent
993 retrograde signal at neuromuscular junctions. *Cell*, 133(5), 903-915.
994 doi:10.1016/j.cell.2008.04.035

995 Snel, B., Lehmann, G., Bork, P., & Huynen, M. A. (2000). STRING: a web-server to retrieve
996 and display the repeatedly occurring neighbourhood of a gene. *Nucleic Acids Res*,
997 28(18), 3442-3444. doi:10.1093/nar/28.18.3442

998 Stark, A., Brennecke, J., Bushati, N., Russell, R. B., & Cohen, S. M. (2005). Animal
999 MicroRNAs confer robustness to gene expression and have a significant impact on
1000 3'UTR evolution. *Cell*, 123(6), 1133-1146. doi:10.1016/j.cell.2005.11.023

1001 Tharyan, R. G., Annibal, A., Schiffer, I., Laboy, R., Atanassov, I., Weber, A. L., . . . Antebi, A.
1002 (2020). NFYB-1 regulates mitochondrial function and longevity via lysosomal
1003 prosaposin. *Nat Metab*, 2(5), 387-396. doi:10.1038/s42255-020-0200-2

1004 Wang, S., Wong, L. Y., Neumann, D., Liu, Y., Sun, A., Antoons, G., . . . Luiken, J. (2020).
1005 Augmenting Vacuolar H(+)-ATPase Function Prevents Cardiomyocytes from Lipid-
1006 Overload Induced Dysfunction. *Int J Mol Sci*, 21(4). doi:10.3390/ijms21041520

1007 Weber, J. A., Baxter, D. H., Zhang, S., Huang, D. Y., Huang, K. H., Lee, M. J., . . . Wang, K.
1008 (2010). The microRNA spectrum in 12 body fluids. *Clin Chem*, 56(11), 1733-1741.
1009 doi:10.1373/clinchem.2010.147405

1010 Wust, S., Drose, S., Heidler, J., Wittig, I., Klockner, I., Franko, A., . . . Braun, T. (2018).
1011 Metabolic Maturation during Muscle Stem Cell Differentiation Is Achieved by miR-
1012 1/133a-Mediated Inhibition of the Dlk1-Dio3 Mega Gene Cluster. *Cell Metab*, 27(5),
1013 1026-1039 e1026. doi:10.1016/j.cmet.2018.02.022

1014 Xu, J., Cao, D., Zhang, D., Zhang, Y., & Yue, Y. (2020). MicroRNA-1 facilitates hypoxia-
1015 induced injury by targeting NOTCH3. *J Cell Biochem*, 121(11), 4458-4469.
1016 doi:10.1002/jcb.29663

1017 Zhang, C. S., Jiang, B., Li, M., Zhu, M., Peng, Y., Zhang, Y. L., . . . Lin, S. C. (2014). The
1018 lysosomal v-ATPase-Ragulator complex is a common activator for AMPK and
1019 mTORC1, acting as a switch between catabolism and anabolism. *Cell Metab*, 20(3),
1020 526-540. doi:10.1016/j.cmet.2014.06.014

1021 Zhao, Y., Ransom, J. F., Li, A., Vedantham, V., von Drehle, M., Muth, A. N., . . . Srivastava,
1022 D. (2007). Dysregulation of cardiogenesis, cardiac conduction, and cell cycle in mice
1023 lacking miRNA-1-2. *Cell*, 129(2), 303-317. doi:10.1016/j.cell.2007.03.030

1024

1025

1026 **Acknowledgements**

1027

1028 AA would like to thank the MPI-AGE proteomics and imaging cores for services, the
1029 Caenorhabditis Genetics Center (CGC, University of Minnesota) for worm strains, the
1030 Bundesministerium für Bildung und Forschung for Sybacol funding, the Deutscher
1031 Akademischer Austauschdienst for funding, and the Max Planck Gesellschaft for core
1032 institutional support. MAM would like to thank Fundação de Amparo à Pesquisa do
1033 Estado de São Paulo (FAPESP) (Grant number 2019/25958-9) and Coordenação de
1034 Aperfeiçoamento de Pessoal de Nível Superior CAPES (Grant number
1035 88881.143924/2017-01) for funding.

1036

1037 **Contributions**

1038

1039 IS, BG, KK, RL, JH, MSD, YS, AA designed and performed experiments
1040 IS, BG, SV, OS, AA wrote the paper

1041


1042

1043

1044

1045 **Supplementary data**

1046




1047

1048 **Supplementary Figure 1. (linked to Figure 1)**

1049 (A) TaqMan qPCR measuring mature *miR-1* levels show that the deletion alleles do not express *miR-1*
 1050 and are null, N=2 BR. mean \pm SEM, one way ANOVA, *, p<0.05.

1051 (B) Brood size of *mir-1(gk276)* and *mir-1(dh1111)* compared to wild-type (N2). Each dot represents the
1052 brood size of one worm, mean \pm SEM, one way ANOVA, ns, not significant.
1053 (C) and (D) Lifespan experiments performed at 20°C and 25°C for two *mir-1* deletion alleles compared
1054 to wild-type. N=3. Not significant (Supplemental Table 1).
1055 (E) and (F) Motility of wild-type and *mir-1(gk276)* mutant animals on day 14 of adulthood, measured by
1056 circle test (E) and thrashing in liquid (F). One representative experiment of each N=3 is shown. Mean \pm
1057 SEM, one way ANOVA, ns, not significant.
1058 (G) Pharyngeal pumping rate measured on day 14 in two *mir-1* alleles compared to wild-type. N=3, one
1059 representative experiment is shown. Mean \pm SEM, one way ANOVA, ns, not significant.
1060 (H) Heat stress survival at 35°C of day 1 *mir-1(gk276)* and *mir-1 (dh1111)* mutants compared to wild-
1061 type. One representative experiment is shown, N=3, t-test: N2 vs. *gk276*: p=0.20. N2 vs. *dh1111*:
1062 p=0.17.
1063 (I) to (M) CeleST locomotion behaviour analyses of wild-type and *mir-1(gk276)* mutant animals with or
1064 without *unc-54p::Q35::YFP*, at day 4 and day 8 of adulthood. Each dot represents one animal. (I) travel
1065 speed (J) wave initiation rate (K) asymmetry (L) stretch, and (M) curling. t-test, *, p<0.05, **, p<0.01,
1066 ***, p<0.001, ns, not significant.
1067 (N) Bar graph showing the expression level of mature miR-1 microRNA in the indicated genotypes. N=1
1068 biological replicate, 4 technical replicates.
1069
1070
1071




1072

1073 **Supplementary Figure 2. (linked to Figure 2)**

1074 (A) v-ATPase subunits containing one or two predicted miR-1 binding sides (BS) in their 3'UTR. v-
 1075 ATPase genes identified in the bioinformatic screen by all three databases are labelled „B“, by 2
 1076 databases are labelled „(B)“ and by the proteomic screen are labelled „P“.
 1077 (B) Correlation plot of the biological replicates from proteomics showing the similarity of WT (N2) and
 1078 *mir-1* genotypes.

1079 **(C)** RNAi screen for genes required for *mir-1(gk276);Q35* motility in the circle test, using upregulated
1080 genes from the proteomic analysis (Supplemental Tables 5 and 6). Each dot represents the percentage
1081 of worms that left the circle. Red line, percent luciferase controls that left the circle. Nd, not determined.
1082 Validation of selected candidates identified from bioinformatic **(D)** and **(E)** proteomic screens by
1083 thrashing assay on day 8 of adulthood. *mir-1(gk276);Q35* worms were grown on the corresponding
1084 RNAi from L4 onwards. Each dot represents one animal, 15 worms per RNAi. Mean \pm SEM, one way
1085 ANOVA, only significant values are labelled: *, p<0.05.
1086 **(F)** Motility of worms in circle test of indicated RNAi on N2;Q35 worms. Motility was measured on day 5
1087 of adulthood, each dot represents the percentage of worms that left the circle. Mean \pm SEM of one
1088 representative experiment, N=3, one way ANOVA, ***, p<0.001, ns, not significant.
1089
1090



Supplementary Figure 3. (linked to Figure 3)

1091

1092 **(A)** Quantification of pharyngeal fluorescent intensity of endogenous *3xFlag::mNeon Green::vha-5* expression in indicated genotypes in late L4s maintained at 25°C. One representative experiment of N=3, mean \pm SEM, t-test, ***, p<0.001.

1093 **(B)** Quantification of fluorescent intensity of *3xFlag::mNeonGreen::vha-5* expression in the vulva of indicated genotypes. Mean \pm SEM of N=3, t-test, ns, not significant.

1094 **(C)** Schematic showing the conservation of miR-1 binding sites (BS) in the *vha-13* 3'UTR of different nematode species.


1095 **(D)** Images showing expression of endogenously tagged *3xFlag::mNeonGreen::vha-13* in muscle dense body and hypodermis. Arrows indicate individual dense bodies. Rectangle highlights muscle section shown in Figure 3B.

1096 **(E)** Quantification of fluorescence intensity in the isthmus of L4 larvae with endogenously tagged *3xFlag::mNeonGreen::vha-13* with *vha-13* MUT1 3' UTR in relation to *vha-13* wt 3'UTR, in N2 and *mir-1(gk276)* mutant backgrounds using confocal microscopy. Mean \pm SEM of one representative experiment. N=2, one way ANOVA, ****, p<0.00001, ns not significant.

1097 **(F)** Thrashing assay of *unc-54p::Q35::YFP* (Q35) worms expressing *vha-13* in body wall muscle (*myo3p::vha-13* wt; Q35) or non-transgenic Q35 animals. 25 worms per genotype, mean \pm SEM of one representative experiment, N=4, t-test, ****, p<0.0001.

1110 (G) Life span of Q35 worms overexpressing *vha-13* in the body wall muscle (*myo3p::vha-13* wt;Q35)
1111 and Q35 non-transgenic segregants of the same strain. One experiment of N=4. Life span effects of two
1112 experiments were significant (Supplemental Table 1). t-test: 0.0017.
1113
1114

1115



1116

1117 **Supplementary Figure 4. (linked to Figure 4)**

1118 **(A)** Fluorescent image comparing HLH-30::mNeonGreen intensity in the pharynx of the *mir-1(gk276)*
1119 and WT (N2) backgrounds in L4s (top) or day 4 adults (D4, bottom). Scale bar 20 μ m **(B)** Quantitation
1120 of nuclear localization in **(A)**, dots represent individual animals. N=2 biological replicates for L4 and N=1
1121 for day 4 adults, t-test, ns: not significant.

1122

1123
1124 Supplemental Table 1: Lifespan and heat stress data.
1125 Supplemental Table 2: Q35 aggregate and behavior data.
1126 Supplemental Table 3: CeleSt data.
1127 Supplemental Table 4: Bioinformatic screen data.
1128 Supplemental Table 5: RNAi motility screen.
1129 Supplemental Table 6: Proteomic analysis of differentially regulated proteins in *mir-1*
1130 vs. wildtype.
1131 Supplemental Table 7: Microscopy data.
1132 Supplemental Table 8: Primers.